miRagen Therapeutics In Strategic, Funding Deal With Servier
Boulder-based miRagen Therapeutics said this week that it has inked a strategic deal with French pharmaceutical company Servier. According to the companies, they have extended a research collaboration on discovering, developing, and commercializing drugs targeting microRNAs for cardiovascular disease. Financial details of the deal were not announced, however, miRagen reported a $7M fundraising in an SEC filing this week. The two said the deal will extend its collaboration to October of 2016. miRagen is led by William S. Marshall. The company is backed by Amgen Ventures, Atlas Venture, Boulder Ventures, Broadview Ventures, Remeditex Ventures, and The Perierls Foundation.
posted on Friday, June 27, 2014
Related companies:
Miragen Therapeutics
Related stories:
> miRagen Therapeutics Finds $20M
> Miragen Therapeutics Gains $3.0M More
> miRagen Therapeutics Raises $40M, Goes Public In Reverse Merger
> Miragen Therapeutics Raises $8M
> miRagen Therapeutics Gets $4M
Techrockies.com Home